New incident report
Incident Report Number: 2023-4163
Registrant Reference Number: 2023-CA-000267
Registrant Name (Full Legal Name no abbreviations): The Hartz Mountain Corporation
Address: 400 Plaza Drive
City: Secaucus
Prov / State: New Jersey
Country: USA
Postal Code: 07094-3688
Domestic Animal
Country: CANADA
Prov / State: MANITOBA
PMRA Registration No. 30728 PMRA Submission No. EPA Registration No.
Product Name: Hartz UltraGuard Pro Drops for Dogs 6 - 14 kg Spot-on
Yes
Unknown
Site: Animal / Usage sur un animal domestique
No
Animal's Owner
Dog / Chien
Shih Tzu/Yorkshire Terrier crossbred
1
Male
2
4.0
kg
Skin
>15 min <=2 hrs / >15 min <=2 h
>30 min <=2 hrs / >30 min <=2 h
System
>30 min <=2 hrs / >30 min <=2 h
Yes
No
Fully Recovered / Complètement rétabli
Treatment / Traitement
(eg. description of the frequency and severity of the symptoms
On 30-Jun-2023, a 2 year old, approximately 4.0 kilogram, neutered, male, Shih Tzu/Yorkshire Terrier crossbred dog, in unknown condition, with no known concomitant medical condition, was administered 1 tube of Hartz UltraGuard Pro Drops for Dogs 6 - 14 kg (Phenothrin (Sumithrin) / S Methoprene) via the topical route by the animal owner. This was an extra label use due to overdose. Approximately 45 minutes post application, the dog developed hyperactivity (agitation). The animal owner consulted with their veterinarian via telephone. The dog was bathed with an unknown amount of unspecified baby shampoo via the topical route by the animal owner, as directed by their veterinarian. The clinical sign resolved and the dog recovered within approximately 1 hour. No further information was received.
Minor
The information contained in this report is based on self-reported statements provided to the registrant during telephone interview(s). These self-reported descriptions of an incident have not been independently verified to be factually correct or complete descriptions of the incident. For that reason, information contained in this report does not and cannot form the basis for a determination of whether the reported clinical effects are causally related to exposure to the product identified in the telephone interviews.